ADVERTORIAL FEATURE
Domestic help
Please remember that the value of an investment can fall and you may not get back the amount invested
Two seemingly unrelated questions : How do we best treat the estimated 40 per cent rise in bowel cancer cases predicted in the next two decades ? Why does the cost of sending money across international borders remain so high and the charges incurred so opaque ? For Milena Mileva , the connection is that they are two of the ‘ hard global problems ’ that Baillie Gifford UK Growth Trust companies – electrosurgery specialist Creo Medical and Wise , a foreign exchange fintech – are addressing . She believes that the portfolio ’ s up-and-coming companies , “ disruptors at the leading edge of innovation ,” are well placed for growth over a 10-year time horizon . Already , she says , they ’ re “ bucking the perception that the UK is not a very exciting place to invest ”. Mileva highlights UK companies taking on some of the biggest global challenges :
The firm develops medical devices for surgical endoscopy – operations carried out by tiny devices inserted into the body via small incisions . Speedboat , its leading product , is attached to an endoscope and used to cut out or vaporise pre-cancerous growths in the digestive tract before they spread . “ Creo enables medics to detect diseases and intervene earlier , giving a better chance of recovery ,” Mileva explains . “ Endoscopes are traditionally only used in investigative procedures to diagnose disease . Creo ’ s advanced energy platform and set of surgical tools enable endoscopes to perform treatments . These procedures benefit the patient and save money
/ 18 / trustnet . com